Literature DB >> 19519534

Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression.

Yu-Wen E Chang1, Ronald R Bean, Rolf Jakobi.   

Abstract

Elevated RhoA/Rho kinase and p21-activated kinase signaling have been shown to promote cancer development and metastasis and have drawn much attention as potential targets of anti-cancer therapy. Elevated RhoA and Rho kinase activity promote cancer cell invasion and eventually lead to metastasis by disrupting E-cadherin-mediated adherens junctions and degradation of the extracellular matrix. Elevated p21-activated kinase activity promotes invasion by stimulating cell motility but also promotes cancer cell survival and growth. In this review we describe normal functions of RhoA/Rho kinase and p21-activated kinase signaling, mechanisms that lead to constitutive activation of RhoA/Rho kinase and p21-activated kinase pathways, and processes by which constitutive RhoA/Rho kinase and p21-activated kinase activity promote cancer development and progression to more aggressive and metastatic phenotypes. In addition, we summarize relevant patents on RhoA/Rho kinase and p21-activated kinase as targets of anti-cancer therapy and discuss the clinical potential of different approaches to modulate RhoA/Rho kinase and p21-activated kinase signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519534     DOI: 10.2174/157489209788452830

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  8 in total

1.  Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells.

Authors:  Catharine A Street; Alissa A Routhier; Carrie Spencer; Ashley L Perkins; Katherine Masterjohn; Alexander Hackathorn; John Montalvo; Emily A Dennstedt; Brad A Bryan
Journal:  Int J Oncol       Date:  2010-11       Impact factor: 5.650

Review 2.  RhoA/Rho-kinase and vascular diseases: what is the link?

Authors:  Kenia Pedrosa Nunes; Christine S Rigsby; R Clinton Webb
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

3.  Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.

Authors:  O Shinto; M Yashiro; H Kawajiri; K Shimizu; T Shimizu; A Miwa; K Hirakawa
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

4.  Effect of shRNA targeted against RhoA on proliferation and migration of human colonic cancer cells.

Authors:  Man Wang; Xiu-Jie Wang; Bing-Rong Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.

Authors:  Li Deng; Yingying Zhang; Lulu Ma; Xiaolong Jing; Xingfa Ke; Jianhao Lian; Qiang Zhao; Bo Yan; Jinfeng Zhang; Jianzhong Yao; Jianming Chen
Journal:  Int J Nanomedicine       Date:  2013-08-26

6.  The effects of knockdown of rho-associated kinase 1 and zipper-interacting protein kinase on gene expression and function in cultured human arterial smooth muscle cells.

Authors:  Jing-Ti Deng; Xiu-Ling Wang; Yong-Xiang Chen; Edward R O'Brien; Yu Gui; Michael P Walsh
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

7.  Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells.

Authors:  Xiaowen Zhang; Nan Wu
Journal:  Drug Des Devel Ther       Date:  2018-02-23       Impact factor: 4.162

8.  Induction of oligodendrocyte differentiation and in vitro myelination by inhibition of rho-associated kinase.

Authors:  Carlos E Pedraza; Christopher Taylor; Albertina Pereira; Michelle Seng; Chui-Se Tham; Michal Izrael; Michael Webb
Journal:  ASN Neuro       Date:  2014-06-25       Impact factor: 4.146

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.